| Functional footprinting of regulatory DNA J Vierstra, A Reik, KH Chang, S Stehling-Sun, Y Zhou, SJ Hinkley, ... Nature methods 12 (10), 927-930, 2015 | 154 | 2015 |
| Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major N Psatha, A Reik, S Phelps, Y Zhou, D Dalas, E Yannaki, DN Levasseur, ... Molecular Therapy Methods & Clinical Development 10, 313-326, 2018 | 117 | 2018 |
| Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing C Li, N Psatha, P Sova, S Gil, H Wang, J Kim, C Kulkarni, C Valensisi, ... Blood, The Journal of the American Society of Hematology 131 (26), 2915-2928, 2018 | 79 | 2018 |
| Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and … E Yannaki, T Papayannopoulou, E Jonlin, F Zervou, G Karponi, ... Molecular Therapy 20 (1), 230-238, 2012 | 72 | 2012 |
| HDAd5/35++ adenovirus vector expressing anti-CRISPR peptides decreases CRISPR/Cas9 toxicity in human hematopoietic stem cells C Li, N Psatha, S Gil, H Wang, T Papayannopoulou, A Lieber Molecular Therapy-Methods & Clinical Development 9, 390-401, 2018 | 71 | 2018 |
| Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy G Karponi, N Psatha, CW Lederer, JE Adair, F Zervou, N Zogas, ... Blood, The Journal of the American Society of Hematology 126 (5), 616-619, 2015 | 58 | 2015 |
| In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia H Wang, A Georgakopoulou, N Psatha, C Li, C Capsali, HB Samal, ... The Journal of clinical investigation 129 (2), 598-615, 2019 | 53 | 2019 |
| A combined in vivo HSC transduction/selection approach results in efficient and stable gene expression in peripheral blood cells in mice H Wang, M Richter, N Psatha, C Li, J Kim, J Liu, A Ehrhardt, SK Nilsson, ... Molecular Therapy-Methods & Clinical Development 8, 52-64, 2018 | 41 | 2018 |
| Integrating HDAd5/35++ vectors as a new platform for HSC gene therapy of hemoglobinopathies C Li, N Psatha, H Wang, M Singh, HB Samal, W Zhang, A Ehrhardt, ... Molecular Therapy Methods & Clinical Development 9, 142-152, 2018 | 31 | 2018 |
| Genetics of the peloponnesean populations and the theory of extinction of the medieval peloponnesean Greeks G Stamatoyannopoulos, A Bose, A Teodosiadis, F Tsetsos, A Plantinga, ... European journal of human genetics 25 (5), 637-645, 2017 | 29 | 2017 |
| Optimizing autologous cell grafts to improve stem cell gene therapy N Psatha, G Karponi, E Yannaki Experimental hematology 44 (7), 528-539, 2016 | 29 | 2016 |
| The diverse genetic origins of a Classical period Greek army LJ Reitsema, A Mittnik, B Kyle, G Catalano, PF Fabbri, ACS Kazmi, ... Proceedings of the National Academy of Sciences 119 (41), e2205272119, 2022 | 27 | 2022 |
| Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo N Psatha, A Georgakopoulou, C Li, V Nandakumar, G Georgolopoulos, ... Blood, The Journal of the American Society of Hematology 138 (17), 1540-1553, 2021 | 23 | 2021 |
| Brief report: a differential transcriptomic profile of ex vivo expanded adult human hematopoietic stem cells empowers them for engraftment better than their surface phenotype N Psatha, G Georgolopoulos, S Phelps, T Papayannopoulou Stem Cells Translational Medicine 6 (10), 1852-1858, 2017 | 23 | 2017 |
| Superior Long-Term Repopulating Capacity of G-CSF+Plerixafor-Mobilized Blood: Implications for Stem Cell Gene Therapy by Studies in the Hbbth-3 Mouse Model N Psatha, E Sgouramali, A Gkountis, A Siametis, P Baliakas, ... Human Gene Therapy Methods 25 (6), 317-327, 2014 | 17 | 2014 |
| Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia E Yannaki, N Psatha, E Athanasiou, G Karponi, V Constantinou, ... Human gene therapy 21 (3), 299-310, 2010 | 16 | 2010 |
| A new era for hemoglobinopathies: more than one curative option N Psatha, PG Papayanni, E Yannaki Current gene therapy 17 (5), 364-378, 2017 | 15 | 2017 |
| Precision editing as a therapeutic approach for β-hemoglobinopathies K Paschoudi, E Yannaki, N Psatha International Journal of Molecular Sciences 24 (11), 9527, 2023 | 12 | 2023 |
| Empowering the potential of CAR-T cell immunotherapies by epigenetic reprogramming M Alvanou, M Lysandrou, P Christophi, N Psatha, A Spyridonidis, ... Cancers 15 (7), 1935, 2023 | 11 | 2023 |
| “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients K Koukoulias, PG Papayanni, A Georgakopoulou, M Alvanou, S Laidou, ... Frontiers in Immunology 11, 608701, 2021 | 11 | 2021 |
